ERBB2 and cancer: None of the patients in the PERSIST study received trastuzumab emtansine (T-DM1), which is now a standard of care for HER2-positive patients with residual cancer after neoadjuvant therapy based on the phase III KATHERINE trial (Liang et al., 2024).